Clarus Ventures

Galera Therapeutics is a clinical-stage biopharmaceutical company focused on developing therapeutics to mitigate radiotherapy-induced side effects in cancer patients. Its lead product candidate, avasopasem manganese (GC4419), is a small molecule superoxide dismutase mimetic currently in Phase III trials for treating radiation-induced severe oral mucositis in head and neck cancer patients.

Avrobio is a clinical-stage biotechnology company focused on developing ex vivo lentiviral-based gene therapies to treat rare diseases with a single dose. Its pipeline includes AVR-RD-01 for Fabry disease, AVR-RD-02 for type 1 Gaucher disease, and AVR-RD-03 for Pompe disease.

Forty Seven, Inc. is a clinical-stage immuno-oncology company headquartered in Menlo Park, California, focused on developing innovative therapies to activate macrophages for cancer treatment. The company’s lead product, magrolimab, is a humanized monoclonal antibody targeting the CD47 receptor, which tumors exploit to evade immune detection. Magrolimab is currently undergoing Phase 1b/2 clinical trials for various cancers, including solid tumors and hematologic malignancies such as acute myeloid leukemia and non-Hodgkin's lymphoma. Additionally, Forty Seven is advancing other antibody-based therapies, including FSI-189, which targets SIRPa, and FSI-174, an anti-cKIT antibody. The company collaborates with Genentech and Acerta Pharma to explore further applications of its therapies in combination with other cancer treatments. Founded in 2014 and previously known as CD47 Sciences, Inc., Forty Seven operates as a subsidiary of Gilead Sciences, Inc.

Gritstone bio is a biotechnology company focused on developing immunotherapies for cancer and infectious diseases. The company initially concentrated on tumor-specific neoantigens but has expanded its programs to include viral antigens found on the surface of infected cells. Gritstone bio's approach leverages the body's natural immune system recognition of targets on abnormal cells, which is applicable to both anti-tumor and anti-viral immunity. Their pipeline includes several product candidates for treating solid tumors, such as GRANITE, SLATE, and CORAL. The company operates in a field that has seen significant advancements with the development and commercialization of immunotherapy drugs like checkpoint inhibitors, transforming cancer treatment.

PATH is an international nonprofit organization that transforms global health through innovation. It takes an entrepreneurial approach to developing and delivering high‑impact, low‑cost solutions, from lifesaving vaccines and devices to collaborative programs with communities. Through its work in more than 70 countries, PATH and its partners empower people to achieve their full potential.

Cleave Therapeutics, Inc. is a biopharmaceutical company based in San Francisco, California, founded in 2010. The company focuses on developing novel small-molecule drugs that target valosin-containing protein and other protein-degradation pathways critical for the survival of cancer cells. By creating enzyme inhibitors designed to disrupt these pathways, Cleave Therapeutics aims to address both oncological and neurodegenerative diseases. Through its innovative approach to drug discovery, the company seeks to provide effective therapeutic solutions that enhance patient outcomes in the fight against cancer.

Avrobio is a clinical-stage biotechnology company focused on developing ex vivo lentiviral-based gene therapies to treat rare diseases with a single dose. Its pipeline includes AVR-RD-01 for Fabry disease, AVR-RD-02 for type 1 Gaucher disease, and AVR-RD-03 for Pompe disease.

Annexon Biosciences is a clinical-stage biopharmaceutical company focused on developing novel therapies for patients with classical complement-mediated disorders affecting the body, brain, and eye. The company's pipeline is built on a platform technology that targets well-researched autoimmune and neurodegenerative disease processes triggered by the aberrant activation of C1q, the initiating molecule of the classical complement pathway. Annexon's lead product candidate, ANX005, is a full-length monoclonal antibody designed for intravenous administration to treat autoimmune and neurodegenerative disorders. Another key candidate, ANX007, is a monoclonal antibody Fab formulated for intravitreal administration to address neurodegenerative ophthalmic disorders. The company employs a biomarker-driven development strategy to ensure that its product candidates effectively engage the target at therapeutic doses within the intended patient tissue, while also exploring additional orphan and large market indications.

Flowonix Medical, Inc. is a medical device company focused on developing implantable drug delivery systems to address chronic neurological disorders. The company specializes in creating devices that facilitate the precise infusion of therapeutic drugs directly into the spine, thereby enhancing treatment efficacy for patients experiencing long-term pain. Its product lineup includes the Prometra drug delivery system, which administers Infumorph, a medication designed for pain management, along with the Prometra Pump and a catheter that aids in the accurate placement of medication within the intrathecal space. Established in 2005 and headquartered in Mount Olive, New Jersey, Flowonix also maintains an office in Mansfield, Massachusetts, and is committed to improving patients' quality of life through innovative technology and reliable medical solutions.

Graybug Vision, Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative treatments for diseases affecting the retina and optic nerve. Founded in 2011 and based in Redwood City, California, the company focuses on chronic vision-threatening conditions. Its lead product candidate, GB-102, is an intravitreal injection undergoing clinical trials for wet age-related macular degeneration and diabetic macular edema. Additionally, Graybug is advancing GB-103, a once-a-year formulation aimed at treating diabetic retinopathy, and GB-401, a depot formulation targeting primary open-angle glaucoma. The company utilizes proprietary micro- and nanoparticle controlled release technologies to enhance drug delivery in ocular tissues, thereby improving patient compliance and clinical outcomes. Graybug Vision was previously known as Graybug LLC before its rebranding in 2016.

Lumos Pharma, Inc. is a clinical-stage biopharmaceutical company based in Austin, Texas, focused on developing and commercializing therapeutics for severe, rare, and genetic diseases. The company's lead product, LUM-201, is an oral small molecule currently undergoing Phase 2 clinical trials for pediatric growth hormone deficiency. In addition to its primary focus, Lumos has a licensing agreement with Ellipses Pharma Limited for the development and commercialization of nanoparticle formulations aimed at oncology indications. Founded in 2011, Lumos Pharma also has a commitment to addressing Creatine Transporter Deficiency, leveraging exclusive licenses for technologies developed at the University of Cincinnati and collaborating with key opinion leaders and the National Institutes of Health. The company engages in both clinical and preclinical research, exploring treatments that may enhance immune responses against cancer, and has partnerships for manufacturing its therapeutics.

Entasis Therapeutics is a biopharmaceutical company focused on developing novel antibacterial products to treat serious infections caused by multi-drug resistant gram-negative bacteria. Its pipeline includes ETX2514SUL for Acinetobacter baumannii infections, ETX0282CPDP for Enterobacteriaceae infections, and zoliflodacin for Neisseria gonorrhoeae.

Forty Seven, Inc. is a clinical-stage immuno-oncology company headquartered in Menlo Park, California, focused on developing innovative therapies to activate macrophages for cancer treatment. The company’s lead product, magrolimab, is a humanized monoclonal antibody targeting the CD47 receptor, which tumors exploit to evade immune detection. Magrolimab is currently undergoing Phase 1b/2 clinical trials for various cancers, including solid tumors and hematologic malignancies such as acute myeloid leukemia and non-Hodgkin's lymphoma. Additionally, Forty Seven is advancing other antibody-based therapies, including FSI-189, which targets SIRPa, and FSI-174, an anti-cKIT antibody. The company collaborates with Genentech and Acerta Pharma to explore further applications of its therapies in combination with other cancer treatments. Founded in 2014 and previously known as CD47 Sciences, Inc., Forty Seven operates as a subsidiary of Gilead Sciences, Inc.

ESSA Pharma Inc. is a clinical-stage pharmaceutical company based in Vancouver, Canada, established in 2009. The company is dedicated to developing innovative therapies for prostate cancer, particularly advanced stages of the disease. Its lead product candidate, EPI-7386, is an oral medication currently undergoing a Phase I clinical study aimed at treating patients with metastatic castration-resistant prostate cancer. ESSA's research focuses on small molecule drugs that selectively inhibit the N-terminal domain of the androgen receptor, a critical component for the growth and survival of prostate cancer cells. This strategic targeting represents a promising avenue for next-generation hormone therapy in the treatment of prostate cancer.

Gritstone bio is a biotechnology company focused on developing immunotherapies for cancer and infectious diseases. The company initially concentrated on tumor-specific neoantigens but has expanded its programs to include viral antigens found on the surface of infected cells. Gritstone bio's approach leverages the body's natural immune system recognition of targets on abnormal cells, which is applicable to both anti-tumor and anti-viral immunity. Their pipeline includes several product candidates for treating solid tumors, such as GRANITE, SLATE, and CORAL. The company operates in a field that has seen significant advancements with the development and commercialization of immunotherapy drugs like checkpoint inhibitors, transforming cancer treatment.

Nuvelution Pharma provides capital solutions and risk-sharing collaborations for pharmaceutical and biotechnology companies to advance product development. Leveraging industry knowledge and relationships, it deploys capital alongside human resources to support late-stage assets and enable financing flexibility, helping clients progress research and bring products with significant commercial potential to market. The company focuses on enabling pharma and biotech firms to overcome budget constraints through collaborative finance and resource sharing, with a view to delivering medicines to patients. Based in Pembroke, Massachusetts.

Annexon Biosciences is a clinical-stage biopharmaceutical company focused on developing novel therapies for patients with classical complement-mediated disorders affecting the body, brain, and eye. The company's pipeline is built on a platform technology that targets well-researched autoimmune and neurodegenerative disease processes triggered by the aberrant activation of C1q, the initiating molecule of the classical complement pathway. Annexon's lead product candidate, ANX005, is a full-length monoclonal antibody designed for intravenous administration to treat autoimmune and neurodegenerative disorders. Another key candidate, ANX007, is a monoclonal antibody Fab formulated for intravitreal administration to address neurodegenerative ophthalmic disorders. The company employs a biomarker-driven development strategy to ensure that its product candidates effectively engage the target at therapeutic doses within the intended patient tissue, while also exploring additional orphan and large market indications.

Flowonix Medical, Inc. is a medical device company focused on developing implantable drug delivery systems to address chronic neurological disorders. The company specializes in creating devices that facilitate the precise infusion of therapeutic drugs directly into the spine, thereby enhancing treatment efficacy for patients experiencing long-term pain. Its product lineup includes the Prometra drug delivery system, which administers Infumorph, a medication designed for pain management, along with the Prometra Pump and a catheter that aids in the accurate placement of medication within the intrathecal space. Established in 2005 and headquartered in Mount Olive, New Jersey, Flowonix also maintains an office in Mansfield, Massachusetts, and is committed to improving patients' quality of life through innovative technology and reliable medical solutions.

Restoration Robotics is a privately held medical device company focused on advancing hair transplantation technology. It has developed the ARTAS™ System, an innovative image-guided platform that facilitates follicular unit extraction, enhancing the precision and efficiency of hair restoration procedures. By integrating advanced imaging and robotics, Restoration Robotics aims to improve outcomes for patients seeking hair transplants, positioning itself as a leader in the evolving field of hair restoration. The company is committed to transforming traditional practices through its state-of-the-art technology.

Imago BioSciences, Inc. is a clinical-stage biotechnology company based in Redwood City, California, founded in 2012. The company specializes in developing novel small molecule therapeutics aimed at treating hematologic diseases, including myelodysplastic syndromes, acute myelogenous leukemia, and other conditions associated with bone marrow failure. Central to its research is the enzyme lysine-specific demethylase 1 (LSD1), which is involved in the regulation of blood cell production. Imago BioSciences is focused on translating advanced scientific insights into transformative therapies that can alter the course of disease, thereby enhancing the quality and longevity of life for patients. Its lead product candidate, Bomedemstat, is an orally administered LSD1 inhibitor currently under evaluation for its potential to modify disease progression in patients with myeloproliferative neoplasms, a group of chronic bone marrow cancers.

Astria Therapeutics is a biopharmaceutical company focused on developing therapies for rare and niche allergic and immunological diseases. It is advancing monoclonal antibody programs such as STAR-0215, a plasma kallikrein inhibitor being developed for hereditary angioedema, and STAR-0310, an OX40 antagonist for atopic dermatitis, both in preclinical development to address immune-mediated inflammatory conditions.

SFJ Pharmaceuticals accelerates global access to innovative drugs by supporting pharmaceutical and biotech companies in clinical development and registration. Established in 2008, the company offers strategic expertise and funding, taking full clinical and regulatory risk without burdening partners' financial resources.

Heptares Therapeutics Ltd. is a clinical-stage drug discovery company based in Welwyn Garden City, United Kingdom, founded in 2007. It specializes in developing novel small-molecule medicines that target G protein-coupled receptors (GPCRs), a significant family of druggable targets associated with various human diseases. Heptares has pioneered a proprietary technology that enables the creation of purified, stabilized, and functional GPCRs, known as StaRs (Stabilised Receptors), which addresses key challenges in the drug development process. The company offers a range of services including GPCR structure-based drug design, X-ray crystallography, surface plasmon resonance, fragment screening, and antibody discovery. Heptares has established strategic partnerships with several organizations, including Pfizer Inc., Kymab Limited, PeptiDream Inc., and Jitsubo Co., Ltd., to enhance its research and development capabilities. As of 2015, Heptares operates as a subsidiary of Sosei Group Corporation.

NanoString Technologies provides life science tools for translational research and molecular diagnostics. It offers the nCounter Analysis System, featuring automated liquid handling and digital detection, along with customizable assays and software for data analysis. The company also develops spatial genomics systems like GeoMx DSP and Hyb & Seq. Its products enable various applications in basic research, translational medicine, and diagnostics.

SFJ Pharmaceuticals accelerates global access to innovative drugs by supporting pharmaceutical and biotech companies in clinical development and registration. Established in 2008, the company offers strategic expertise and funding, taking full clinical and regulatory risk without burdening partners' financial resources.

Pearl Therapeutics develops innovative combination therapies for treating prevalent respiratory diseases like COPD, focusing on improving accessibility via familiar inhalers. Led by experienced experts, the company aims to enhance clinical outcomes by offering alternatives that surpass existing treatments' safety and efficacy.

Astria Therapeutics is a biopharmaceutical company focused on developing therapies for rare and niche allergic and immunological diseases. It is advancing monoclonal antibody programs such as STAR-0215, a plasma kallikrein inhibitor being developed for hereditary angioedema, and STAR-0310, an OX40 antagonist for atopic dermatitis, both in preclinical development to address immune-mediated inflammatory conditions.

NanoString Technologies provides life science tools for translational research and molecular diagnostics. It offers the nCounter Analysis System, featuring automated liquid handling and digital detection, along with customizable assays and software for data analysis. The company also develops spatial genomics systems like GeoMx DSP and Hyb & Seq. Its products enable various applications in basic research, translational medicine, and diagnostics.

Pearl Therapeutics develops innovative combination therapies for treating prevalent respiratory diseases like COPD, focusing on improving accessibility via familiar inhalers. Led by experienced experts, the company aims to enhance clinical outcomes by offering alternatives that surpass existing treatments' safety and efficacy.

Pearl Therapeutics develops innovative combination therapies for treating prevalent respiratory diseases like COPD, focusing on improving accessibility via familiar inhalers. Led by experienced experts, the company aims to enhance clinical outcomes by offering alternatives that surpass existing treatments' safety and efficacy.

SFJ Pharmaceuticals accelerates global access to innovative drugs by supporting pharmaceutical and biotech companies in clinical development and registration. Established in 2008, the company offers strategic expertise and funding, taking full clinical and regulatory risk without burdening partners' financial resources.

SFJ Pharmaceuticals accelerates global access to innovative drugs by supporting pharmaceutical and biotech companies in clinical development and registration. Established in 2008, the company offers strategic expertise and funding, taking full clinical and regulatory risk without burdening partners' financial resources.

Oxford Immunotec is a diagnostics company specializing in the development and commercialization of proprietary tests for immunology and infectious diseases. Headquartered in the UK, with operations in the US, the company's core technology, T-SPOT, measures specific T cell responses to inform diagnosis, prognosis, and monitoring of patients with immune-regulated conditions. Its flagship product, T-SPOT.TB, detects active and latent tuberculosis infection, while T-SPOT.CMV monitors cytomegalovirus in transplant recipients. Oxford Immunotec serves independent laboratories, hospital systems, and public and private institutions worldwide.

SFJ Pharmaceuticals accelerates global access to innovative drugs by supporting pharmaceutical and biotech companies in clinical development and registration. Established in 2008, the company offers strategic expertise and funding, taking full clinical and regulatory risk without burdening partners' financial resources.

Sientra is a medical device company based in Santa Barbara, California, specializing in breast implant treatments for both augmentation and reconstruction. Founded by Hani Zeini, the company develops innovative implantable devices that cater to the needs of plastic surgeons. Sientra's product offerings include silicone gel breast implants, breast tissue expanders, and silicone scar treatment solutions, focusing on providing elegant and intuitive options for cosmetic and reconstructive surgery. The company's commitment to quality and innovation positions it as a significant player in the surgical aesthetics market.

Astria Therapeutics is a biopharmaceutical company focused on developing therapies for rare and niche allergic and immunological diseases. It is advancing monoclonal antibody programs such as STAR-0215, a plasma kallikrein inhibitor being developed for hereditary angioedema, and STAR-0310, an OX40 antagonist for atopic dermatitis, both in preclinical development to address immune-mediated inflammatory conditions.

Cleave Therapeutics, Inc. is a biopharmaceutical company based in San Francisco, California, founded in 2010. The company focuses on developing novel small-molecule drugs that target valosin-containing protein and other protein-degradation pathways critical for the survival of cancer cells. By creating enzyme inhibitors designed to disrupt these pathways, Cleave Therapeutics aims to address both oncological and neurodegenerative diseases. Through its innovative approach to drug discovery, the company seeks to provide effective therapeutic solutions that enhance patient outcomes in the fight against cancer.

NanoString Technologies provides life science tools for translational research and molecular diagnostics. It offers the nCounter Analysis System, featuring automated liquid handling and digital detection, along with customizable assays and software for data analysis. The company also develops spatial genomics systems like GeoMx DSP and Hyb & Seq. Its products enable various applications in basic research, translational medicine, and diagnostics.

Restoration Robotics is a privately held medical device company focused on advancing hair transplantation technology. It has developed the ARTAS™ System, an innovative image-guided platform that facilitates follicular unit extraction, enhancing the precision and efficiency of hair restoration procedures. By integrating advanced imaging and robotics, Restoration Robotics aims to improve outcomes for patients seeking hair transplants, positioning itself as a leader in the evolving field of hair restoration. The company is committed to transforming traditional practices through its state-of-the-art technology.

SARcode Bioscience is a private biopharmaceutical company based in San Francisco, focused on developing a novel class of small molecule lymphocyte function-associated antigen-1 (LFA-1) antagonists. These antagonists are designed to serve as topical agents for addressing significant unmet medical needs in ophthalmology, dermatology, and other inflammatory diseases. By targeting LFA-1, SARcode aims to create innovative therapeutic solutions to improve patient outcomes in these areas.

Aerie Pharmaceuticals is a biotechnology company dedicated to the discovery, development, and commercialization of innovative therapies for various eye diseases. Founded in 2005, the company has its headquarters in Bridgewater, New Jersey, and research facilities in Research Triangle Park, North Carolina. Aerie's portfolio includes Rhopressa, a once-daily eye drop to reduce elevated intraocular pressure (IOP) in patients with glaucoma or ocular hypertension; Rocklatan, a fixed-dose combination of Rhopressa and latanoprost for similar indications; AVX-012, a clinical-stage product candidate for dry eye; and AR-1105 and AR-13503 sustained-release implants for retinal diseases. The company collaborates with DSM on research, development, and licensing agreements.

TetraLogic Pharmaceuticals is a privately held biopharmaceutical company focused on the discovery and development of small molecule drugs that target programmed cell death pathways to address serious diseases. The company's lead products, known as Smac Mimetics, work by neutralizing key inhibitors in the apoptosis pathway, allowing for the selective destruction of cancer cells. Additionally, TetraLogic develops Necrostatin drugs, which inhibit critical processes leading to necrosis, thus promoting cell survival in various conditions where necrosis plays a significant role in disease progression. Through these innovative therapeutic approaches, TetraLogic aims to improve treatment outcomes in oncology and other medical fields.

Astria Therapeutics is a biopharmaceutical company focused on developing therapies for rare and niche allergic and immunological diseases. It is advancing monoclonal antibody programs such as STAR-0215, a plasma kallikrein inhibitor being developed for hereditary angioedema, and STAR-0310, an OX40 antagonist for atopic dermatitis, both in preclinical development to address immune-mediated inflammatory conditions.

TyRx specializes in the development of resorbable polymeric biomaterials. It offers PIVIT CRM, an antibacterial mesh pouch protecting implantable cardiac devices from microbial infections during and post-surgery, and AIGISRx Flat, an antibacterial product safeguarding pacemakers and defibrillators against infections.

TetraLogic Pharmaceuticals is a privately held biopharmaceutical company focused on the discovery and development of small molecule drugs that target programmed cell death pathways to address serious diseases. The company's lead products, known as Smac Mimetics, work by neutralizing key inhibitors in the apoptosis pathway, allowing for the selective destruction of cancer cells. Additionally, TetraLogic develops Necrostatin drugs, which inhibit critical processes leading to necrosis, thus promoting cell survival in various conditions where necrosis plays a significant role in disease progression. Through these innovative therapeutic approaches, TetraLogic aims to improve treatment outcomes in oncology and other medical fields.

Taligen Therapeutics is a biotechnology company dedicated to discovering and developing novel protein therapeutics aimed at modulating the alternative pathway of the complement system. This approach targets a critical amplification loop in the inflammatory process, which is significant for treating a variety of inflammatory conditions and diseases. The company's lead therapeutic candidates include monoclonal antibodies and recombinant fusion proteins designed to interact with key factors in the alternative pathway. By focusing on the regulation of the complement system, Taligen Therapeutics seeks to provide innovative solutions for inflammatory and immune diseases.

Achillion Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in Blue Bell, Pennsylvania, specializing in the discovery, development, and commercialization of small molecule drug therapies targeting immune system disorders. Its lead candidate, ACH-4471, is a factor D inhibitor currently undergoing Phase II clinical trials for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and C3 glomerulopathy. The company is also advancing other factor D inhibitors, including ACH-5228 and ACH-5548, both of which are in Phase I clinical trials for PNH and other complement-mediated diseases. Achillion has established license agreements with Ora, Inc. for the development of ACH-702 and with GCA Therapeutics, Ltd. for elvucitabine, a treatment for hepatitis B and HIV. Founded in 1998, Achillion operates as a subsidiary of Alexion Pharmaceuticals, Inc. Its focus is on advancing therapies that address disorders linked to the complement system, which plays a crucial role in the innate immune response.

TetraLogic Pharmaceuticals is a privately held biopharmaceutical company focused on the discovery and development of small molecule drugs that target programmed cell death pathways to address serious diseases. The company's lead products, known as Smac Mimetics, work by neutralizing key inhibitors in the apoptosis pathway, allowing for the selective destruction of cancer cells. Additionally, TetraLogic develops Necrostatin drugs, which inhibit critical processes leading to necrosis, thus promoting cell survival in various conditions where necrosis plays a significant role in disease progression. Through these innovative therapeutic approaches, TetraLogic aims to improve treatment outcomes in oncology and other medical fields.

Zogenix, Inc. is a pharmaceutical company focused on developing and commercializing innovative therapies for patients with rare diseases, particularly within the central nervous system. The company is headquartered in Emeryville, California, and was established in 2006. Its lead product candidate, Fintepla, is a low-dose fenfluramine currently undergoing Phase III clinical trials for the treatment of seizures related to Dravet syndrome and Lennox-Gastaut syndrome. Additionally, it is being investigated in Phase II trials for other rare epileptic conditions. Zogenix is also developing MT1621, a therapy aimed at treating inherited mitochondrial DNA depletion disorders. Furthermore, the company collaborates with Tevard Biosciences to explore gene therapies for Dravet syndrome and similar genetic epilepsies. By focusing on therapies that address significant unmet medical needs, Zogenix aims to enhance the quality of life for patients and their families.

Ferrokin Biosciences Inc. develops and markets medical devices. The company offers iron chelator for the treatment of iron-overload in patients with transfusion-dependent hereditary and acquired refractory anemias. The company is based in San Carlos, California.

Oxford Immunotec is a diagnostics company specializing in the development and commercialization of proprietary tests for immunology and infectious diseases. Headquartered in the UK, with operations in the US, the company's core technology, T-SPOT, measures specific T cell responses to inform diagnosis, prognosis, and monitoring of patients with immune-regulated conditions. Its flagship product, T-SPOT.TB, detects active and latent tuberculosis infection, while T-SPOT.CMV monitors cytomegalovirus in transplant recipients. Oxford Immunotec serves independent laboratories, hospital systems, and public and private institutions worldwide.

Astria Therapeutics is a biopharmaceutical company focused on developing therapies for rare and niche allergic and immunological diseases. It is advancing monoclonal antibody programs such as STAR-0215, a plasma kallikrein inhibitor being developed for hereditary angioedema, and STAR-0310, an OX40 antagonist for atopic dermatitis, both in preclinical development to address immune-mediated inflammatory conditions.

Lycera is a preclinical-stage biopharmaceutical company dedicated to developing small molecule immunomodulators aimed at treating autoimmune diseases, including rheumatoid arthritis, lupus erythematosus, and inflammatory bowel disease. The company focuses on creating first-in-class drugs that leverage proprietary technology platforms, including small molecules that modulate a target central to cellular bioenergetics and molecules that target the Th17 pathway. By utilizing ATPase modulators, Lycera’s drug candidates are designed to offer oral efficacy while minimizing the adverse effects associated with conventional antiproliferative and immunosuppressive treatments. Through its innovative approach, Lycera aims to provide effective therapeutic options for patients suffering from various immune-related conditions.

NanoString Technologies provides life science tools for translational research and molecular diagnostics. It offers the nCounter Analysis System, featuring automated liquid handling and digital detection, along with customizable assays and software for data analysis. The company also develops spatial genomics systems like GeoMx DSP and Hyb & Seq. Its products enable various applications in basic research, translational medicine, and diagnostics.

Pearl Therapeutics develops innovative combination therapies for treating prevalent respiratory diseases like COPD, focusing on improving accessibility via familiar inhalers. Led by experienced experts, the company aims to enhance clinical outcomes by offering alternatives that surpass existing treatments' safety and efficacy.

Neomend is a biomedical device company focused on developing and commercializing innovative surgical wound healing products. The company's primary technology is Pro/PEG, a bioadhesive polymer hydrogel designed to enhance the healing process. Neomend specializes in a combination wound sealant and adhesion barrier product that can be utilized during minimally invasive and laparoscopic procedures, improving patient outcomes and recovery times. Through its advanced technological solutions, Neomend aims to address critical needs in surgical wound management.

IVERIC bio is a biopharmaceutical company dedicated to discovering and developing innovative treatments for retinal diseases that have significant unmet medical needs. The company is actively working on therapeutic product candidates aimed at age-related retinal diseases, as well as gene therapy product candidates designed for orphan inherited retinal diseases. By focusing on these areas, IVERIC bio aims to address critical gaps in the current treatment landscape for patients suffering from various retinal conditions.

Virdante Pharmaceuticals, established in 2007 and headquartered in Cambridge, Massachusetts, specializes in developing and marketing drugs targeting autoimmune and inflammatory diseases. Its product portfolio comprises antibody and Fc-fusion drugs designed to address these conditions.

Ferrokin Biosciences Inc. develops and markets medical devices. The company offers iron chelator for the treatment of iron-overload in patients with transfusion-dependent hereditary and acquired refractory anemias. The company is based in San Carlos, California.

Zogenix, Inc. is a pharmaceutical company focused on developing and commercializing innovative therapies for patients with rare diseases, particularly within the central nervous system. The company is headquartered in Emeryville, California, and was established in 2006. Its lead product candidate, Fintepla, is a low-dose fenfluramine currently undergoing Phase III clinical trials for the treatment of seizures related to Dravet syndrome and Lennox-Gastaut syndrome. Additionally, it is being investigated in Phase II trials for other rare epileptic conditions. Zogenix is also developing MT1621, a therapy aimed at treating inherited mitochondrial DNA depletion disorders. Furthermore, the company collaborates with Tevard Biosciences to explore gene therapies for Dravet syndrome and similar genetic epilepsies. By focusing on therapies that address significant unmet medical needs, Zogenix aims to enhance the quality of life for patients and their families.

NanoString Technologies provides life science tools for translational research and molecular diagnostics. It offers the nCounter Analysis System, featuring automated liquid handling and digital detection, along with customizable assays and software for data analysis. The company also develops spatial genomics systems like GeoMx DSP and Hyb & Seq. Its products enable various applications in basic research, translational medicine, and diagnostics.

Lycera is a preclinical-stage biopharmaceutical company dedicated to developing small molecule immunomodulators aimed at treating autoimmune diseases, including rheumatoid arthritis, lupus erythematosus, and inflammatory bowel disease. The company focuses on creating first-in-class drugs that leverage proprietary technology platforms, including small molecules that modulate a target central to cellular bioenergetics and molecules that target the Th17 pathway. By utilizing ATPase modulators, Lycera’s drug candidates are designed to offer oral efficacy while minimizing the adverse effects associated with conventional antiproliferative and immunosuppressive treatments. Through its innovative approach, Lycera aims to provide effective therapeutic options for patients suffering from various immune-related conditions.

Aerovance is a privately held biopharmaceutical company exclusively focused on developing and commercializing breakthrough medicines for respiratory and allergic diseases. The company maintains a solid intellectual property position with its strong portfolio of novel therapeutic candidates now in clinical development and several pre-clinical programs. The two lead products are human recombinant proteins: Aerovantâ„¢, an IL-4 and -13 receptor antagonist which is in Phase IIa studies for asthma and Aerodermâ„¢, a PEGylated IL-4 and IL-13 receptor antagonist in pre-clinical studies for eczema.

SFJ Pharmaceuticals accelerates global access to innovative drugs by supporting pharmaceutical and biotech companies in clinical development and registration. Established in 2008, the company offers strategic expertise and funding, taking full clinical and regulatory risk without burdening partners' financial resources.

Heptares Therapeutics Ltd. is a clinical-stage drug discovery company based in Welwyn Garden City, United Kingdom, founded in 2007. It specializes in developing novel small-molecule medicines that target G protein-coupled receptors (GPCRs), a significant family of druggable targets associated with various human diseases. Heptares has pioneered a proprietary technology that enables the creation of purified, stabilized, and functional GPCRs, known as StaRs (Stabilised Receptors), which addresses key challenges in the drug development process. The company offers a range of services including GPCR structure-based drug design, X-ray crystallography, surface plasmon resonance, fragment screening, and antibody discovery. Heptares has established strategic partnerships with several organizations, including Pfizer Inc., Kymab Limited, PeptiDream Inc., and Jitsubo Co., Ltd., to enhance its research and development capabilities. As of 2015, Heptares operates as a subsidiary of Sosei Group Corporation.

Biolex Therapeutics is a clinical-stage biopharmaceutical company focused on developing therapeutic proteins and monoclonal antibodies using its patented LEX System. This innovative technology genetically transforms the aquatic plant Lemna to facilitate the production of biologic product candidates that are challenging to manufacture. Biolex's primary product is designed to address the needs of patients afflicted with Hepatitis C, aiming to improve treatment outcomes through enhanced efficacy and potency of its therapeutic offerings.

Link Medicine is a privately held biotechnology company established in 2005 by Peter Lansbury, a prominent neuroscience researcher from Harvard University, along with Ed Rudman, a private investor diagnosed with Parkinson's disease, and entrepreneur Adam Rosenberg, who experienced the impact of neurodegenerative diseases in his family. The company focuses on advancing innovative treatments for various neurodegenerative conditions, including Alzheimer's, Parkinson's, Huntington's disease, and Amyotrophic Lateral Sclerosis (ALS). Link Medicine targets a fundamental aspect of these disorders: the accumulation of misfolded and aggregated proteins in nerve cells that can become neurotoxic. By addressing this common feature, Link Medicine aims to develop effective therapies that can alleviate the burden of these debilitating diseases.

ESBATech, founded in 1998 as a spin-out from the University of Zurich, specializes in developing fully human antibody fragments for therapeutic use. The company utilizes its proprietary single-chain antibody frameworks to create product candidates targeting clinically relevant sites. ESBATech's approach aims to deliver high concentrations of these therapeutic fragments directly to targeted areas while minimizing systemic exposure, thereby reducing the risk of adverse drug reactions through topical and local administration methods.

MacroGenics is a biopharmaceutical company focused on discovering and developing antibody-based therapeutics for cancer treatment. Its pipeline includes Margetuximab targeting HER2-expressing tumors, Flotetuzumab for acute myeloid leukemia, and other immuno-oncology product candidates such as MGA012, MGD013, MGD019, and Enoblituzumab. The company also develops combination therapies like MGD009 with MGA012, and antibody drug conjugates like MGC018 targeting B7-H3.

Pearl Therapeutics develops innovative combination therapies for treating prevalent respiratory diseases like COPD, focusing on improving accessibility via familiar inhalers. Led by experienced experts, the company aims to enhance clinical outcomes by offering alternatives that surpass existing treatments' safety and efficacy.

CoMentis, Inc. is a biotechnology company dedicated to the research, discovery, and development of small-molecule drugs aimed at treating neurovascular diseases, particularly Alzheimer's disease and schizophrenia. The company is focused on creating nicotinic acetylcholine receptor modulators to address cognitive disorders. Founded in 2004 as Athenagen, Inc., it underwent a name change to CoMentis in February 2007 after merging with Zapaq, Inc., which strengthened its position in the neurovascular disease sector. CoMentis is headquartered in South San Francisco, California.

Zogenix, Inc. is a pharmaceutical company focused on developing and commercializing innovative therapies for patients with rare diseases, particularly within the central nervous system. The company is headquartered in Emeryville, California, and was established in 2006. Its lead product candidate, Fintepla, is a low-dose fenfluramine currently undergoing Phase III clinical trials for the treatment of seizures related to Dravet syndrome and Lennox-Gastaut syndrome. Additionally, it is being investigated in Phase II trials for other rare epileptic conditions. Zogenix is also developing MT1621, a therapy aimed at treating inherited mitochondrial DNA depletion disorders. Furthermore, the company collaborates with Tevard Biosciences to explore gene therapies for Dravet syndrome and similar genetic epilepsies. By focusing on therapies that address significant unmet medical needs, Zogenix aims to enhance the quality of life for patients and their families.

Taligen Therapeutics is a biotechnology company dedicated to discovering and developing novel protein therapeutics aimed at modulating the alternative pathway of the complement system. This approach targets a critical amplification loop in the inflammatory process, which is significant for treating a variety of inflammatory conditions and diseases. The company's lead therapeutic candidates include monoclonal antibodies and recombinant fusion proteins designed to interact with key factors in the alternative pathway. By focusing on the regulation of the complement system, Taligen Therapeutics seeks to provide innovative solutions for inflammatory and immune diseases.

Pelikan Technologies is dedicated to the development of innovative hand-held diagnostic and monitoring devices capable of significantly improving the screening and management of a variety of medical conditions.

Oxford Immunotec is a diagnostics company specializing in the development and commercialization of proprietary tests for immunology and infectious diseases. Headquartered in the UK, with operations in the US, the company's core technology, T-SPOT, measures specific T cell responses to inform diagnosis, prognosis, and monitoring of patients with immune-regulated conditions. Its flagship product, T-SPOT.TB, detects active and latent tuberculosis infection, while T-SPOT.CMV monitors cytomegalovirus in transplant recipients. Oxford Immunotec serves independent laboratories, hospital systems, and public and private institutions worldwide.

Pearl Therapeutics develops innovative combination therapies for treating prevalent respiratory diseases like COPD, focusing on improving accessibility via familiar inhalers. Led by experienced experts, the company aims to enhance clinical outcomes by offering alternatives that surpass existing treatments' safety and efficacy.

Globus Medical specializes in the development and distribution of medical devices focused on treating musculoskeletal disorders. Its comprehensive product portfolio includes implants for spine surgery, orthopedic trauma solutions, regenerative biologic products, motion preservation technologies, interventional pain management solutions, imaging and robotic-assisted surgery technology, and hip/knee joint solutions.

Sientra is a medical device company based in Santa Barbara, California, specializing in breast implant treatments for both augmentation and reconstruction. Founded by Hani Zeini, the company develops innovative implantable devices that cater to the needs of plastic surgeons. Sientra's product offerings include silicone gel breast implants, breast tissue expanders, and silicone scar treatment solutions, focusing on providing elegant and intuitive options for cosmetic and reconstructive surgery. The company's commitment to quality and innovation positions it as a significant player in the surgical aesthetics market.

Aerovance is a privately held biopharmaceutical company exclusively focused on developing and commercializing breakthrough medicines for respiratory and allergic diseases. The company maintains a solid intellectual property position with its strong portfolio of novel therapeutic candidates now in clinical development and several pre-clinical programs. The two lead products are human recombinant proteins: Aerovantâ„¢, an IL-4 and -13 receptor antagonist which is in Phase IIa studies for asthma and Aerodermâ„¢, a PEGylated IL-4 and IL-13 receptor antagonist in pre-clinical studies for eczema.

Proacta Inc. is a private, clinical-stage, biopharmaceutical company headquartered in San Diego, California. They are focused on addressing unmet needs in the field of cancer with the development of hypoxia-activated prodrugs that target cancer cells. Proacta was founded on intellectual property generated in New Zealand at the University of Auckland and in the United States at Stanford University. Proacta's patent family covers a series of hypoxia-activated prodrugs designed to treat cancer. Expansion of this portfolio is supported by ongoing research at The University of Auckland. PR610 is the lead compound from their pipeline of pro-drugs based on hypoxia-activated tyrosine-kinase inhibitors. These pro-drugs selectively release active tyrosine-kinase inhibitors within the low-oxygen (hypoxic) environment found in many solid tumors. By shifting the release of active drug away from normal tissues and into cancer tissues, these drugs are predicted to be more effective and less toxic than currently available therapies. To date, Proacta has raised $43 million in two private financings. Investors include Alta Partners, Clarus Ventures, Delphi Ventures, Endeavour Capital (New Zealand), GBS Venture Partners (Australia), Genentech, No 8 Ventures (New Zealand) and Roche.

SARcode Bioscience is a private biopharmaceutical company based in San Francisco, focused on developing a novel class of small molecule lymphocyte function-associated antigen-1 (LFA-1) antagonists. These antagonists are designed to serve as topical agents for addressing significant unmet medical needs in ophthalmology, dermatology, and other inflammatory diseases. By targeting LFA-1, SARcode aims to create innovative therapeutic solutions to improve patient outcomes in these areas.

VBI Vaccines Inc. is a biopharmaceutical company based in Cambridge, Massachusetts, with research facilities in Ottawa, Canada. It develops and sells vaccines for infectious diseases and immuno-oncology, with a focus on expanding protection in large, underserved markets. The company's enveloped virus-like particle (eVLP) platform enables the creation of vaccines that closely mimic target viruses, eliciting potent immune responses. VBI's commercial product, Sci-B-Vac, is a hepatitis B vaccine approved in Israel and 14 other countries, offering rapid onset of protection and high antibody levels. The company is also developing VBI-2601 for a functional cure of chronic hepatitis B, VBI-1901 for glioblastoma, and VBI-1501 for cytomegalovirus, among other candidates. VBI collaborates with pharmaceutical companies and research institutions, and its products are primarily distributed through direct sales to physicians and pharmacists.

SARcode Bioscience is a private biopharmaceutical company based in San Francisco, focused on developing a novel class of small molecule lymphocyte function-associated antigen-1 (LFA-1) antagonists. These antagonists are designed to serve as topical agents for addressing significant unmet medical needs in ophthalmology, dermatology, and other inflammatory diseases. By targeting LFA-1, SARcode aims to create innovative therapeutic solutions to improve patient outcomes in these areas.

CoMentis, Inc. is a biotechnology company dedicated to the research, discovery, and development of small-molecule drugs aimed at treating neurovascular diseases, particularly Alzheimer's disease and schizophrenia. The company is focused on creating nicotinic acetylcholine receptor modulators to address cognitive disorders. Founded in 2004 as Athenagen, Inc., it underwent a name change to CoMentis in February 2007 after merging with Zapaq, Inc., which strengthened its position in the neurovascular disease sector. CoMentis is headquartered in South San Francisco, California.

Zogenix, Inc. is a pharmaceutical company focused on developing and commercializing innovative therapies for patients with rare diseases, particularly within the central nervous system. The company is headquartered in Emeryville, California, and was established in 2006. Its lead product candidate, Fintepla, is a low-dose fenfluramine currently undergoing Phase III clinical trials for the treatment of seizures related to Dravet syndrome and Lennox-Gastaut syndrome. Additionally, it is being investigated in Phase II trials for other rare epileptic conditions. Zogenix is also developing MT1621, a therapy aimed at treating inherited mitochondrial DNA depletion disorders. Furthermore, the company collaborates with Tevard Biosciences to explore gene therapies for Dravet syndrome and similar genetic epilepsies. By focusing on therapies that address significant unmet medical needs, Zogenix aims to enhance the quality of life for patients and their families.

ESBATech, founded in 1998 as a spin-out from the University of Zurich, specializes in developing fully human antibody fragments for therapeutic use. The company utilizes its proprietary single-chain antibody frameworks to create product candidates targeting clinically relevant sites. ESBATech's approach aims to deliver high concentrations of these therapeutic fragments directly to targeted areas while minimizing systemic exposure, thereby reducing the risk of adverse drug reactions through topical and local administration methods.